The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of lapatinib in combination with vinorelbine, as first- or second-line therapy in women with HER2-overexpressing metastatic breast cancer.
Helen K. Chew
No relevant relationships to disclose
Lee Steven Schwartzberg
Other Remuneration - GlaxoSmithKline
Suprith Badarinath
No relevant relationships to disclose
Peter Rubin
No relevant relationships to disclose
Grace Shumaker
No relevant relationships to disclose
James P. Daugherty
No relevant relationships to disclose
Michelle DeSilvio
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Janine M. Mahoney
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline